{"componentChunkName":"component---src-templates-study-details-page-js","path":"/en/study/APV10017","result":{"data":{"studyNotFoundJson":{"title":"Study not found","content":{"childMarkdownRemark":{"html":"<p>If you entered a web address please check it was correct.</p>\n<p>You can also try <a href=\"/en/studies\">Search Page</a> to find the study you are looking for.</p>"}}},"trialDetailsJson":{"title":"Details Page","returnSearch":"Back to search results","description":"Study Description","identifier":"ViiV Study ID","clinicalID":"Clinicaltrials.gov Identifier","EudraCtID":"EudraCT Number","resultsAvailable":"Has Results Available Below","docAvailable":"Has Results Document Available","studyOverview":"Study Overview","overviewSection":{"conditionsDisplay":"Medical Conditions","product":"Product","collaborators":"Collaborators","dates":"Date","studyType":"Type","phase":"Phase","gender":"Gender","age":"Age","acceptVolunteers":"Accepts Healthy Volunteers"},"studyDocuments":"Study Documents","noDocuments":"No documents available","studyDocumentsAdditionalText":"If you wish to request for Full Study Report, please contact - ","studyDocumentsAdditionalEmail":"GSKClinicalSupportHD@gsk.com","isReleased":{"firstPart":"This study has Protocol and Result summary on ClinicalTrial.gov. Click","secondPart":"to learn more.","linkText":"here"},"mapLocations":"Locations","centralContact":"Central Contact","centralPhone":"Central Contact Phone","centralEmail":"Central Contact Email","mapSection":{"site":"GSK Investigational Site","condition":"Condition","id":"Study ID","city":"City","state":"State","zip":"Zip","country":"Country"},"studyDesign":"Study Design","designSection":{"purpose":"Primary Purpose","allocation":"Allocation","study_design":"Study Design","study_classification":"Study Classification","masking":"Masking","masked_subject":"Masked Subject","masked_caregiver":"Masked Caregiver","masked_investigator":"Masked Investigator","masked_assessor":"Masked Assessor","primary_outcomes":"Primary Outcomes","secondary_outcomes":"Secondary Outcomes","arms":"Arms","interventions":"Interventions","keyword":"Keyword","inclusionTitle":"Inclusion Criteria","exclusionTitle":"Exclusion Criteria","criteriaText":"Inclusion/Exclusion Criteria","criteria_button":"Click to view inclusion/exclusion criteria","enrollment":"Enrollment","clinicalPublications":"Clinical Publications"},"popoversText":{"studyId":{"childMarkdownRemark":{"html":"<p>A unique number for a study given by ViiV.</p>"}},"ctGov":{"childMarkdownRemark":{"html":"<p>This number identifies the study on the US clinicaltrials.gov register. Click this link to go to the entry for this study on Clinicaltrials.gov where you will be able to see protocol and results summaries where available.</p>"}},"eudraCT":{"childMarkdownRemark":{"html":"<p>This number identifies the study on the EU clinicaltrials.eu register. Click this link to go to the entry for this study on clinicaltrials.eu where you will be able to see protocol and results summaries where available.</p>"}}}},"site":{"siteMetadata":{"siteUrl":"https://www.viiv-studyregister.com"}},"studyDetails":{"nct_number":"","ctis_id":"","HasResults":"false","IpdAccessCriteria":"","IpdDescription":"","IpdInfoTypeAnalyticCode":"","IpdInfoTypeIcf":"","IpdInfoTypeCsr":"","IpdInfoTypeProtocol":"","IpdInfoTypeSap":"","IpdTimeFrame":"","IpdUrl":"","IsFlexibleTrial":false,"IsReleasedToCtGov":"false","MaskingInfo":{"masked_assessor":"false","masked_caregiver":"false","masked_investigator":"false","masked_subject":"false","masking_description":"","no_masking":""},"PatientLevelData":"false","SharingIpd":"","acronym":"","allocation":"Randomized","arm_groups":[],"assignment":"Parallel Assignment","brief_summary":"This study was designed to evaluate plasma amprenavir levels following taking fosamprenavir and ritonavir for two weeks in HIV-1 infected subjects with mild and moderate liver function impairment compared to matched subjects with normal liver function.","brief_summary_OneLinkTx":"","brief_title_OneLinkTx":"","brief_title":"Plasma Amprenavir In HIV-1-Infected Adult Subjects With Liver Function Impairment","conditions":[{"DisplayValue":"Metabolism & Nutrition - Other","DisplayValue_OneLinkTx":"","InternalValue":"CON_METABOLISM_NUTRITION_OTHER","LookupValue":"hepatic impairment","LookupValue_OneLinkTx":""},{"DisplayValue":"Human Immunodeficiency Virus (HIV)","DisplayValue_OneLinkTx":"","InternalValue":"CON_HIV","LookupValue":"HIV Infection","LookupValue_OneLinkTx":""}],"created_date":"09/15/2018 17:43:21","criteria":"Inclusion criteria: - Subjects must have clinically stable HIV disease, in the judgement of the study doctor, for 3 months prior to study entry. - Subjects must be currently on no antiretroviral therapy (ART) or on ART consisting of either: - Nucleoside reverse transcriptase inhibitors (NRTIs) or nucleotide reverse transcriptase inhibitors [N(t)RTIs] and willing to add fosamprenavir and ritonavir for two weeks. - Protease inhibitors (PIs), other than,atazanavir (ATV), ATV/RTV, or tipranavir (TPV)/RTV + NRTIs/N(t)RTIs and willing to discontinue the PI(s) and replace the PI(s) with fosamprenavir and ritonavir for two weeks. - Fosamprenavir with or without ritonavir+ NRTIs/N(t)RTIs and willing to be dosed with the fosamprenavir and ritonavir regimen specified in the protocol for two weeks. - Subjects should have either normal liver function or impaired liver function. To be classified as hepatically impaired, subjects must have: - Known medical history of liver disease with or without a known history of alcohol abuse; and, - Previous confirmation of liver fibrosis by liver biopsy, or macroscopic evaluation by laparoscopy, computerized tomography (CT) scan, magnetic resonance imaging (MRI) or ultrasonography associated with an medical history; and, - Child-Pugh score of 5-6 for classification of mild impairment or 7-9 for moderate impairment, or 10-15 for severe impairment. Note: subjects with hepatic impairment must score equal to or more than 2 for bilirubin, albumin, and/or PT. Exclusion criteria: - Evidence of acute or exacerbating hepatitis. - Advanced ascites, significant bleeding diathesis, esophageal bleeding within the last 8 weeks, significant degree of central nervous system impairment or other signs of hepatic function deterioration. - Subjects with any condition that might interfere with the absorption, distribution, metabolism, or excretion of drugs (except for hepatic impairment). - Subjects have had significant drug or alcohol abuse in the past two months. - Positive Hepatitis B or C test for a subject with normal liver function. - Positive pregnant test for a female subject.","detailed_description":"A Phase I, Parallel, Open-Label, Multicenter, Two Week, Repeat-dose study Evaluating Plasma Amprenavir Pharmacokinetics in HIV-1 Infected Adult Subjects with Mild, Moderate or Severe Hepatic Impairment Receiving Fosamprenavir + Ritonavir Compared to Matched Control Subjects with Normal Hepatic Function","display_gender":"Both","display_gender_internal":"GENDER_ALL","display_phase":"Phase 1","display_phase_internal":"PHASE_1","display_status":"Completed","display_status_internal":"RECSTATUS_I_COMPLETED","endpoint":"","enrollment":"60","exclusion":"","gender":"Both","gender_based":"","gender_description":"","healthy_volunteers":"No","id":"d30e5ee8-0072-54a1-a2db-b09d26076b43","internal":{"content":null,"contentDigest":"660d74d0aad1527ff889e32009afec20","description":null,"fieldOwners":null,"mediaType":null,"ignoreType":null,"owner":"default-site-plugin","type":"studyDetails"},"inclusion":"Inclusion criteria: - Subjects must have clinically stable HIV disease, in the judgement of the study doctor, for 3 months prior to study entry. - Subjects must be currently on no antiretroviral therapy (ART) or on ART consisting of either: - Nucleoside reverse transcriptase inhibitors (NRTIs) or nucleotide reverse transcriptase inhibitors [N(t)RTIs] and willing to add fosamprenavir and ritonavir for two weeks. - Protease inhibitors (PIs), other than,atazanavir (ATV), ATV/RTV, or tipranavir (TPV)/RTV + NRTIs/N(t)RTIs and willing to discontinue the PI(s) and replace the PI(s) with fosamprenavir and ritonavir for two weeks. - Fosamprenavir with or without ritonavir+ NRTIs/N(t)RTIs and willing to be dosed with the fosamprenavir and ritonavir regimen specified in the protocol for two weeks. - Subjects should have either normal liver function or impaired liver function. To be classified as hepatically impaired, subjects must have: - Known medical history of liver disease with or without a known history of alcohol abuse; and, - Previous confirmation of liver fibrosis by liver biopsy, or macroscopic evaluation by laparoscopy, computerized tomography (CT) scan, magnetic resonance imaging (MRI) or ultrasonography associated with an medical history; and, - Child-Pugh score of 5-6 for classification of mild impairment or 7-9 for moderate impairment, or 10-15 for severe impairment. Note: subjects with hepatic impairment must score equal to or more than 2 for bilirubin, albumin, and/or PT. Exclusion criteria: - Evidence of acute or exacerbating hepatitis. - Advanced ascites, significant bleeding diathesis, esophageal bleeding within the last 8 weeks, significant degree of central nervous system impairment or other signs of hepatic function deterioration. - Subjects with any condition that might interfere with the absorption, distribution, metabolism, or excretion of drugs (except for hepatic impairment). - Subjects have had significant drug or alcohol abuse in the past two months. - Positive Hepatitis B or C test for a subject with normal liver function. - Positive pregnant test for a female subject.","interventions":[{"arm_group_label":"","intervention_description":"","intervention_name":"Fosamprenavir","intervention_type":"Drug"},{"arm_group_label":"","intervention_description":"","intervention_name":"Ritonavir","intervention_type":"Drug"}],"interventional_subtype":"Treatment","is_fda_regulated":null,"is_high_value":false,"is_ind_study":true,"keywords":["LEXIVA","protease inhibitors","GW433908","ritonavir boosted PI","ritonavir","fosamprenavir","hepatic impairment","HIV infection","amprenavir"],"last_follow_up_date":"10/01/2007 00:00:00","links":[],"locations":[{"City":"Marid","Latitude":"40.4473608","CountryDisplay":"Spain","Longitude":"-3.7384311","Name":"GSK Investigational Site","StateDisplay":null,"PostalCode":"28040","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Los Angeles","Latitude":"34.1220545","CountryDisplay":"United States","Longitude":"-118.2935891","Name":"GSK Investigational Site","StateDisplay":"California","PostalCode":"90027","StatusDisplay":"Withdrawn","StatusDisplayInternal":"LOCSTATUS_TERMINATED","StatusMapped":"Terminated/Withdrawn"},{"City":"Granada","Latitude":"37.1850036","CountryDisplay":"Spain","Longitude":"-3.6496505","Name":"GSK Investigational Site","StateDisplay":null,"PostalCode":"18003","StatusDisplay":"Recruiting","StatusDisplayInternal":"LOCSTATUS_RECRUITING","StatusMapped":"Recruiting"},{"City":"Long Beach","Latitude":"33.7844997","CountryDisplay":"United States","Longitude":"-118.1971031","Name":"GSK Investigational Site","StateDisplay":"California","PostalCode":"90813","StatusDisplay":"Withdrawn","StatusDisplayInternal":"LOCSTATUS_TERMINATED","StatusMapped":"Terminated/Withdrawn"},{"City":"Sevilla","Latitude":"37.3040307","CountryDisplay":"Spain","Longitude":"-4.8728093","Name":"GSK Investigational Site","StateDisplay":null,"PostalCode":"41041","StatusDisplay":"Recruiting","StatusDisplayInternal":"LOCSTATUS_RECRUITING","StatusMapped":"Recruiting"},{"City":"Bakersfield","Latitude":"35.3873576","CountryDisplay":"United States","Longitude":"-119.0168962","Name":"GSK Investigational Site","StateDisplay":"California","PostalCode":"93301","StatusDisplay":"Withdrawn","StatusDisplayInternal":"LOCSTATUS_TERMINATED","StatusMapped":"Terminated/Withdrawn"},{"City":"Madrid","Latitude":"40.4063013","CountryDisplay":"Spain","Longitude":"-3.6699295","Name":"GSK Investigational Site","StateDisplay":null,"PostalCode":"28007","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Santiago De Compostela","Latitude":"42.8663831","CountryDisplay":"Spain","Longitude":"-8.5638609","Name":"GSK Investigational Site","StateDisplay":null,"PostalCode":"15706","StatusDisplay":"Recruiting","StatusDisplayInternal":"LOCSTATUS_RECRUITING","StatusMapped":"Recruiting"},{"City":"Barcelona","Latitude":"41.3899238","CountryDisplay":"Spain","Longitude":"2.1511635","Name":"GSK Investigational Site","StateDisplay":null,"PostalCode":"08036","StatusDisplay":"Recruiting","StatusDisplayInternal":"LOCSTATUS_RECRUITING","StatusMapped":"Recruiting"},{"City":"New York","Latitude":"40.7916407","CountryDisplay":"United States","Longitude":"-73.9447994","Name":"GSK Investigational Site","StateDisplay":"New York","PostalCode":"10029","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Madrid","Latitude":"40.4998271","CountryDisplay":"Spain","Longitude":"-3.6876803","Name":"GSK Investigational Site","StateDisplay":null,"PostalCode":"28034","StatusDisplay":"Recruiting","StatusDisplayInternal":"LOCSTATUS_RECRUITING","StatusMapped":"Recruiting"},{"City":"Sevilla","Latitude":"37.2878009","CountryDisplay":"Spain","Longitude":"-5.4882679","Name":"GSK Investigational Site","StateDisplay":null,"PostalCode":"41071","StatusDisplay":"Recruiting","StatusDisplayInternal":"LOCSTATUS_RECRUITING","StatusMapped":"Recruiting"},{"City":"San Juan","Latitude":"18.4465407","CountryDisplay":"Puerto Rico","Longitude":"-66.067938","Name":"GSK Investigational Site","StateDisplay":null,"PostalCode":"00909-1711","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Altamonte Springs","Latitude":"28.6659654","CountryDisplay":"United States","Longitude":"-81.3729372","Name":"GSK Investigational Site","StateDisplay":"Florida","PostalCode":"32701","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Hampton","Latitude":"37.0538822","CountryDisplay":"United States","Longitude":"-76.3984537","Name":"GSK Investigational Site","StateDisplay":"Virginia","PostalCode":"23666","StatusDisplay":"Withdrawn","StatusDisplayInternal":"LOCSTATUS_TERMINATED","StatusMapped":"Terminated/Withdrawn"},{"City":"Cartagena (Murcia)","Latitude":"37.6106974","CountryDisplay":"Spain","Longitude":"-0.9748978","Name":"GSK Investigational Site","StateDisplay":null,"PostalCode":"30203","StatusDisplay":"Withdrawn","StatusDisplayInternal":"LOCSTATUS_TERMINATED","StatusMapped":"Terminated/Withdrawn"},{"City":"Bakersfield","Latitude":"35.3873576","CountryDisplay":"United States","Longitude":"-119.0168962","Name":"GSK Investigational Site","StateDisplay":"California","PostalCode":"93301","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Valencia","Latitude":"39.4781137","CountryDisplay":"Spain","Longitude":"-0.363067","Name":"GSK Investigational Site","StateDisplay":null,"PostalCode":"46010","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Madrid","Latitude":"40.3672276","CountryDisplay":"Spain","Longitude":"-3.6978264","Name":"GSK Investigational Site","StateDisplay":null,"PostalCode":"28041","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Fort Lauderdale","Latitude":"26.1897731","CountryDisplay":"United States","Longitude":"-80.1037721","Name":"GSK Investigational Site","StateDisplay":"Florida","PostalCode":"33308","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Los Angeles","Latitude":"34.0931603","CountryDisplay":"United States","Longitude":"-118.3783347","Name":"GSK Investigational Site","StateDisplay":"California","PostalCode":"90069","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Madrid","Latitude":"40.4765501","CountryDisplay":"Spain","Longitude":"-3.7003632","Name":"GSK Investigational Site","StateDisplay":null,"PostalCode":"28029","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"New York","Latitude":"40.74727","CountryDisplay":"United States","Longitude":"-73.9800645","Name":"GSK Investigational Site","StateDisplay":"New York","PostalCode":"10016","StatusDisplay":"Withdrawn","StatusDisplayInternal":"LOCSTATUS_TERMINATED","StatusMapped":"Terminated/Withdrawn"},{"City":"Elche (Alicante)","Latitude":"38.2751042","CountryDisplay":"Spain","Longitude":"-0.6749327","Name":"GSK Investigational Site","StateDisplay":null,"PostalCode":"03202","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Badalona","Latitude":"41.474766","CountryDisplay":"Spain","Longitude":"2.2285864","Name":"GSK Investigational Site","StateDisplay":null,"PostalCode":"08916","StatusDisplay":"Recruiting","StatusDisplayInternal":"LOCSTATUS_RECRUITING","StatusMapped":"Recruiting"},{"City":"Madrid","Latitude":"40.4731818","CountryDisplay":"Spain","Longitude":"-3.6864121","Name":"GSK Investigational Site","StateDisplay":null,"PostalCode":"28046","StatusDisplay":"Recruiting","StatusDisplayInternal":"LOCSTATUS_RECRUITING","StatusMapped":"Recruiting"}],"masking":"Open Label","maximum_age_raw":"65 years","maximum_age":"65","minimum_age":"18","minimum_age_raw":"18 years","modified_date":"10/01/2018 22:58:28","number_of_arms":"","observational_design":{"biospecimen_description":"","biospecimen_retention":"","number_of_groups":"","observational_study_design":"","patient_registry":"","target_duration_quantity":"","target_duration_units":"","timing":""},"official_title":"A Phase I, Parallel, Open-label, Multicenter, Two-Week, Repeat-dose Study Evaluating Plasma Amprenavir Pharmacokinetics in HIV-1-infected Adult Subjects with Mild, Moderate or Severe Hepatic Impairment Receiving Fosamprenavir + Ritonavir Compared to Matched Control Subjects with Normal Hepatic Function","org_study_id":"APV10017","overall_contact":{"email":"GSKClinicalSupportHD@gsk.com","last_name":"Call Center","phone":"877-379-3718"},"overall_status":"Completed - Interventional","oversight_info":{"exported_from_us":"","fda_regulated_device":"","fda_regulated_drug":"","ped_postmarket_surv":"","has_dmc":false,"post_prior_to_approval":"","regulatory_authorities":[""]},"phase":"Phase 1","primary_compl_date":"10/01/2007 00:00:00","primary_outcomes":[{"outcome_description":"","outcome_measure":"amprenavir pharmacokinetic parameters","outcome_time_frame":"2 Weeks","outcome_safety_issue":null}],"product_name":"","product_name_OneLinkTx":"","secondary_ids":[],"secondary_outcomes":[{"outcome_description":"","outcome_measure":"ritonavir pharmacokinetic parameters laboratory assessments","outcome_time_frame":"2 Weeks","outcome_safety_issue":null}],"sponsors":{"investigator_affiliation":"","investigator_username":"","lead_sponsor":"ViiV Healthcare","collaborators":[]},"start_date":"11/01/2004 00:00:00","study_type":"Interventional","therapeutic_area":"Infectious Diseases","citations":[],"is_section_801":null}},"pageContext":{"studyId":"APV10017"}},"staticQueryHashes":["162689979","3332233851","3729204765","3769354840","399703114"]}